AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reissued by investment analysts at BNP Paribas in a research note issued on Friday. They presently have a GBX 5,200 ($67.88) target price on the biopharmaceutical company’s stock. BNP Paribas’ price objective would suggest a potential upside of 3.15% from the stock’s current price.
AZN has been the topic of a number of other reports. Societe Generale reissued a “buy” rating and set a GBX 7,000 ($91.37) price target on shares of AstraZeneca plc in a research report on Wednesday, September 14th. Morgan Stanley lifted their price target on shares of AstraZeneca plc from GBX 5,000 ($65.27) to GBX 5,800 ($75.71) and gave the stock an “overweight” rating in a research report on Friday, August 19th. Deutsche Bank AG reissued a “buy” rating and set a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research report on Wednesday, September 28th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price target on shares of AstraZeneca plc and gave the stock a “sell” rating in a research report on Tuesday, September 6th. Finally, Jefferies Group reissued a “buy” rating and set a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research report on Wednesday, September 21st. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. AstraZeneca plc has an average rating of “Hold” and an average price target of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) opened at 5015.00 on Friday. The company’s market capitalization is GBX 63.44 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The firm’s 50-day moving average is GBX 5,007.50 and its 200-day moving average is GBX 4,415.10.
The company also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.90) per share. This represents a dividend yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.